SEARCH

SEARCH BY CITATION

References

  • 1
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907911.
  • 2
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938952.
  • 3
    Wolinsky JS. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci 2003; 206: 145152.
  • 4
    Noseworthy JH. Forward in: FilippiM, ComiG, eds. Topics in neuroscience: primary progressive multiple sclerosis. Milano: Springer-Verlag Italia, 2002: ivv.
  • 5
    McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 2002; 199: 115.
  • 6
    Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler 2004; 10: S8S15.
  • 7
    Wolinsky JS, Narayana PA, He R. Overview of treatment trials: early baseline clinical and MRI data of the PROMiSe trial. In: FilippiM, ComiG, eds. Primary progressive multiple sclerosis. Milano: Springer-Verlag Italia, 2002: 4762.
  • 8
    Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 4451.
  • 9
    Montalban X. Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis. Mult Scler 2004; 10(suppl): S62S64.
  • 10
    Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002; 8: 532533.
  • 11
    Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50: 701708.
  • 12
    Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290297.
  • 13
    Bornstein MB, Miller A, Slagle S, Weitzman M, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533539.
  • 14
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 14441452.
  • 15
    Bedell BJ, Narayana PA, Wolinsky JS. A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997; 37: 94102.
  • 16
    Wolinsky JS, Narayana PA, Johnson KP, Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 2001; 7: 3341.
  • 17
    Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houstonm, Health Science Center, and the North American Linomide Investigators. Neurology 2000; 54: 17341741.
  • 18
    Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112(pt 1): 133146.
  • 19
    Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(pt 1): 117134.
  • 20
    Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122(pt 4): 625639.
  • 21
    Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65: 19191923.
  • 22
    Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 14301438.
  • 23
    Wolinsky JS. The use of glatiramer acetate in the treatment of MS. In: FreedmanM, ed. Multiple sclerosis and demyelinating diseases. Philadelphia: Lippincott Williams & Wilkins, 2006: 273292.
  • 24
    Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001; 124: 25402549.
  • 25
    Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler 2004; 10: S2S7.
  • 26
    Wolinsky JS, Narayana PA. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol 2002; 15: 247251.